While the world awaits an efficient vaccine for coronavirus, many therapeutics are currently being investigated in hope to improve clinical outcomes. One of the most promising one is currently remdesivir. Wang et al. published the first randomised placebo-controlled trial of its use in severe COVID-19.
High intensity statin for secondary prevention after ischaemic stroke is standard of therapy. What should be the level of LDL and if lower levels have better outcomes is less clear. Treat Stroke to Target trial had looked into outcomes of patients after ischaemic stroke treated to higher and lower LDL target.